Akums Q1FY27: Revenue up 13.9% to ₹1,167 Cr, EBITDA soars 35.4% to ₹175 Cr
Akums reported Q1 FY27 revenue of ₹1,167 Cr, up 13.9% YoY, and EBITDA of ₹175 Cr, up 35.4% YoY. The CDMO segment led growth with an 18.6% revenue increase. The company also announced the acquisition of Oriflame India's manufacturing business. Akums maintains a strong cash position of ₹1,616 Cr.
The significant growth in key financial metrics like revenue and EBITDA, coupled with a strategic acquisition and a strong balance sheet, is expected to have a substantial positive impact on the company's market position and investor confidence.
The company reported strong year-on-year growth in revenue and EBITDA, driven by its core CDMO segment. The acquisition of Oriflame India's manufacturing business also indicates strategic expansion. The healthy cash surplus further bolsters a positive outlook.
Akums Drugs and Pharmaceuticals Limited announced its unaudited financial results for the first quarter of FY27, ending June 30, 2026. The company reported a significant year-on-year revenue growth of 13.9%, reaching ₹1,167 crores, compared to ₹1,024 crores in Q1 FY26. EBITDA also saw a substantial increase of 35.4%, rising to ₹175 crores from ₹129 crores in the same period last year. EBITDA margins improved to 15%, up from 12.6% in Q1 FY26.
The growth was primarily driven by the CDMO segment, which reported an 18.6% year-on-year revenue increase to ₹964 crores, with EBITDA growing by 36.8% to ₹163 crores. This performance was attributed to strong volume growth and improved API prices.
Domestic branded formulations (Akumentis) showed a 7.3% revenue growth to ₹115 crores, though EBITDA declined due to increased employee strength. The international branded formulation business experienced a slight revenue decline of 1.5% to ₹35 crores.
The API segment's revenue decreased by 29.7% to ₹32 crores, but losses narrowed to ₹4 crores from ₹6 crores in Q1 FY26. The trade generics segment revenue fell by 9.5% to ₹21 crores, with EBITDA remaining at breakeven.
During the quarter, the company announced the acquisition of Oriflame India's manufacturing business, expanding its footprint in skincare, cosmetics, and wellness products. Akums ended the quarter with a healthy cash surplus of ₹1,616 crores.
What to do with a filing like this
Akums Drugs and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Akums Drugs and Pharmaceuticals Limited. Read the original for the full detail.